Market Reports

A new paradigm in vaccines and cancer treatments

Specialist pharmaceutical company N4 Pharma is developing Nuvec, a unique non-viral adjuvant delivery system for vaccines and cancer treatments. This silica nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. Dr Kevin Robinson recently caught up with Nigel Theobald, CEO of N4 Pharma, to find out more

Fuelling pharma’s innovation engines

Wishing to assess the current state of Alcami’s target market, Dr Kevin Robinson recently sat down with President and CEO, Dr Stephan Kutzer, to discuss its health, innovation and future aspirations

Broad stripes, bright stars and a thriving pharmaceutical industry: part I

According to one of Stephen Sondheim’s most well-known lyrics, “I like to be in America! OK by me in America!” But, given the geography, politics, population, regulation and funding that are unique to the United States, Dr Kevin Robinson looked west to the Land of the Free to find out how the pharmaceutical industry is faring amongst all the milk and honey

The hidden risk of contamination

Pharmaceutical companies may be unwittingly putting production processes at risk of contamination by fitting pumps with mechanical seals that fail to comply with industry regulations, says John Smiddy, European Sales and Technical Support Director for AESSEAL

A revolutionary method of liquid flow measurement

Pharmaceutical supplier opts for innovative hygienic flowmeter

Next-generation safety testing

In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable

Developments and the future of pharmaceutical packaging

With the global primary packaging market in the pharmaceutical sector expected to experience remarkable growth during the next few years, Dr Kevin Robinson asked a number of industry experts to comment on the hurdles, drivers and emerging trends that are influencing how drugs are formulated, packaged and delivered

Is the production of biologic drugs ready for an overhaul?

Is the industry ready for a new manufacturing model? Mark Emalfarb, President and CEO of Dyadic International, thinks so and explains why to Dr Kevin Robinson

Leaders of transformation

Haig Armaghanian, founder and CEO of Haig Barrett, explores how synthetic biology pioneers are revolutionising therapeutic development

Continuous manufacturing: the facts and the future

Many companies talk about continuous manufacturing (CM), but few speak with the experience of actually implementing a continuous process line. Dr Kevin Robinson spoke to GEA’s Richard Steiner to find out why

Looking back on 2018 and making predictions for 2019

As the global pharmaceutical industry transitions from the knowns of 2018 into the unknowns of 2019, Dr Kevin Robinson caught up with some of the key players in the market to assess the year that was and the 12 months to come in terms of upcoming trends and developments

Serialisation is not enough

A global technology leader in supply chain security, Systech’s revolutionary solution provides authentic, safe and connected products throughout the pharmaceutical supply chain. Dr Kevin Robinson recently caught up with CEO Ara Ohanian to find out more

Preparing PIs for post EU-FMD success

Ian Haynes of Excellis Europe explains how the company’s unique approach to enabling collaboration between parallel importers is helping to simplify the transition to serialisation post EU-FMD

Eliminating the time thieves

Comprehensive scientific process engineering (CSPE) cuts delivery times and accelerates the commissioning of pharmaceutical systems. Dr Kevin Robinson spoke to Optima Pharma’s Gerhard Breu to find out more

Formulating for success with ODTs

An ageing global population, consumer demand for greater convenience and the need to improve patient compliance are driving the development of new platforms for orally disintegrating dosage forms

Choosing effective granulation strategies for effervescent formulations

Effervescent tablets and instant drinks are attractive dosage forms for healthcare companies looking to meet the needs of modern patients and consumers

FMD: clarification for wholesalers, distributors and logistics partners

Christian Taylor, Serialisation Business Consultant at Zetes, clears up some of the key pain points when it comes to the practical application of the Falsified Medicines Directive (FMD)

Serialisation and data connectivity: Part II

The new wrinkle in your supply chain, <a href='https://www.manufacturingchemist.com/news/article_page/Serialisation_and_data_connectivity_Part_I/147850'>click here to read part I</a>

Serialisation and data connectivity: Part I

The new wrinkle in your supply chain

A grandmaster’s approach to successful tableting

Tableting is a fundamental unit operation in the production of pharmaceutical oral solid dosage forms. Despite its long history of use and the development of innovations such as extended dwell times, unique technologies that independently and simultaneously measure and control both tablet weight and hardness, and a weight control system that provides increased sensitivity at lower forces, production problems still occur. Here, Dr Harald Stahl, Group Director, Application and Strategy Management, GEA, provides some troubleshooting tips from an unlikely source: the chess board

Discover, learn and connect at Lab Innovations!

Experience the latest developments at the UK’s only event dedicated to the laboratory industry

Pharmacovigilance in the hands of patients

Angharad Baldwin caught up with Dr Andrew Rut, founder of MyMeds&Me, at FutureLink 2018 to talk about what software as a service means to the pharmaceutical industry and the patient ... and whether there’s such a thing as too much data

ATP detection: The balance between precision and speed

Adenosine triphosphate (ATP) is an indicator molecule for the presence of biological residues used in food production. Burcu Yordem, 3M Food Safety, explains its role in an effective hygiene monitoring programme

Making a difference in pharma contract manufacturing

With a plant near Basel, Switzerland, and a heritage of more than 40 years, contract service provider Legacy Pharmaceuticals understands the value of flexibility and experience when producing parenteral and semisolid drugs. Dr Kevin Robinson spoke to Mike Danzi, Chief Executive Officer, to find out more

Trending Articles

  1. Outsourcing in pharma: a comprehensive guide to strategic advantages and considerations Outsourcing in pharma drives agility, compliance, and efficiency—NSF delivers expert audits, training, remediation, and embedded support
  2. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin
  3. Poolbeg granted FDA Orphan Drug Designation for POLB 001 The US FDA grants orphan status to support the development of medicines for rare disorders affecting fewer than 200,000 people in the US
  4. Peak identification by LC/MS: Automation versus analyst High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
  5. The economic advantages of continuous flow chemistry Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit

Upcoming event

POWTECH

23-25 September 2025 | Exhibition | Nuremberg, Germany See all